Can a supercharged TB regimen save more lives in HIV patients?

NCT ID NCT04738812

Completed Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 24, 2026 · Updated 18 times

Summary

This study tested whether a stronger tuberculosis (TB) treatment could reduce deaths in people with HIV who have very low immune cell counts (CD4 ≤ 100). Over 1,300 hospitalized adults and teens received either an intensified drug regimen (with extra rifampicin, isoniazid, prednisone, and albendazole) or the standard WHO TB treatment. The goal was to see if the stronger approach improved survival over 48 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Ignace Deen Hospital

Conakry, Guinea
Jamot Hospital

Yaoundé, Cameroon
MACHAVA Hospital

Maputo, Mozambique
Mbarara Regional Referral hospital

Mbarara, Uganda
National Center for HIV/AIDS, Dermatology and STD (NCHADS)

Phnom Penh, Cambodia
University Teaching Hospital

Lusaka, Zambia

Conditions

Explore the condition pages connected to this study.

HIV-1-INFECTION IMMUNO-DEFICIENCY TUBERCULOSIS